Pedro Ruiz

High-throughput screening for the identification of dual inhibitors of BRD4 and RIPK3 toward the development of small-molecule medical countermeasure agents against arsenicals

Marina Fosso Yatchang, Ling Zhai, Omar Moukha‐Chafiq, Bini Mathew et autres

Warfare arsenicals are potent blistering agents and cause severe inflammation following their skin exposure. Data from our group (unpublished) show that these chemicals act by activating bromodomain-4 and RIPK signaling. To develop a dual inhibitor of the bromodomain-containing protein 4 (BRD4) and …

us (code pays fourni par la source)

A high-throughput human tissue model for respiratory viruses: Automating the use of human airway epithelial tissues for faster drug discovery

N. Miranda Nebane, Andrew Reece, Lynn A. Rasmussen, Melinda Ingrum Sosa et autres

Animal testing for drug discovery is expensive and the decision to test a compound in an in vivo model should be carefully considered. In addition, the FDA Modernization Act has resulted in the allowance of alternatives to animal models for testing the …

us (code pays fourni par la source)

High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay

Yohanka Martinez-Gzegozewska, Lynn A. Rasmussen, N. Miranda Nebane, Sara N. McKellip et autres

A highly sensitive cell-based imaging assay has been used to screen a 200,000 compounds library for potential influenza antivirals. Compounds were screened at a concentration of 10 μM against the influenza strain A/Udorn/72 (H3N2) and the duplex capability of the assay was …

us (code pays fourni par la source)

A high-throughput response to the SARS-CoV-2 pandemic

Lynn A. Rasmussen, S K Sanders, Melinda Ingrum Sosa, Sara N. McKellip et autres

Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was …

us (code pays fourni par la source)

A High-Throughput Human Tissue Model for Respiratory Viruses

Miranda Nebane, Andrew Reece, Lynn A. Rasmussen, Melinda Ingrum Sosa et autres

us (code pays fourni par la source)

Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability

Jonathan R. Roth, Travis Rush, Samantha J. Thompson, Adam R. Aldaher et autres

Alzheimer's disease (AD) is the leading cause of dementia and lacks highly effective treatments. Tau-based therapies hold promise. Tau reduction prevents amyloid-β-induced dysfunction in preclinical models of AD and also prevents amyloid-β-independent dysfunction in diverse disease models, especially those with network hyperexcitability, …

us (code pays fourni par la source)

High-Throughput cell-based immunofluorescence assays against influenza

Yohanka Martinez-Gzegozewska, Lynn A. Rasmussen, Sara N. McKellip, Anna Manuvakhova et autres

A rapid drug discovery response to influenza outbreaks with the potential to reach pandemic status could help minimize the virus's impact by reducing the time to identify anti-influenza drugs. Although several anti-influenza strategies have been considered in the search for new drugs, …

us (code pays fourni par la source)

A Novel Approach To Identify Inhibitors of Iron Acquisition Systems of Pseudomonas aeruginosa

Mamie Kannon, N. Miranda Nebane, Pedro Ruiz, Sara N. McKellip et autres

design of molecules and identifies structurally diverse biologically active inhibitor molecules. This screening approach is adaptable and can be extended to any pathogen. Since Gram-negative pathogens share many similarities in iron acquisition at both the mechanistic and molecular levels, our screening approach …

us (code pays fourni par la source)

Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals

Marina Fosso Yatchang, Bini Mathew, Ritesh K. Srivastava, Jasim Khan et autres

us (code pays fourni par la source)

Development of small‐molecule tau‐SH3 interaction inhibitors that prevent amyloid‐β toxicity

Jonathan R. Roth, Travis Rush, Derian A. Pugh, Hunter B. Dean et autres

Abstract Background Alzheimer’s disease (AD) is the leading cause of dementia and lacks disease‐modifying treatments. Tau‐based therapies are attractive and Tau reduction prevents amyloid‐induced dysfunction in preclinical AD models. Tau reduction also prevents amyloid‐independent dysfunction in diverse disease contexts, suggesting that strategies …

us (code pays fourni par la source)

Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS

Bini Mathew, Pedro Ruiz, Shilpa Dutta, Jordan Thomas Entrekin et autres

us (code pays fourni par la source)

Development of novel small molecules for the treatment of ALS

Bini Mathew, Pedro Ruiz, Vibha Pathak, Mark J. Suto

us (code pays fourni par la source)